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  Antibiotic resistance is a persistent and serious public health issue which causes many 
illnesses and deaths per year. In contrast to the rapid increase and spread of drug-resistant 
bacteria, antibiotic development has slowed, and there is a clear need to identify and develop 
antibiotics with new scaffolds and mechanisms of action. In particular, there is a specific need 
for novel antimicrobial agents which are active against both gram negative and gram positive 
pathogens. The bacterial enzyme MurA catalyzes the transfer of enolpyruvate from 
phosphoenolpyruvate (PEP) to uridine diphospho-N-acetylglucosamine (UNAG), which is the 
first committed step of bacterial cell wall biosynthesis. Currently, the only antibiotic targeted 
toward MurA is fosfomycin, which inhibits MurA by forming a covalent bond with MurA’s 
active site residue, Cys115. However, MurA variants which lack the cysteine residue in the 
active site (e.g. M. tuberculosis MurA and some vancomycin resistant Enterococcus (VRE) 
strains) are resistant to fosfomycin. 
  The goal of this study was to identify novel MurA inhibitors with a different mechanism 
of action than fosfomycin, and which are active against a range of gram negative and gram 
positive bacteria. To this end, we have developed and optimized an in vivo high-throughput 
screening assay to test recombinant MurA enzyme against the TimTec ApexScreen library, a 
drug library with 5,040 structurally diverse compounds. The hits identified from this screen were 
further validated using different assays, including bacterial growth curves. Minimum Inhibitory 
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Concentration (MIC) values were determined for the three most promising hits. Toxicity assays 
for these hits were also conducted in two cell lines. Future directions include further 
characterizing the mechanisms of action and testing for toxicity in other cell lines, including 
primary cells.  
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1.0  INTRODUCTION 
1.1 ANTIBIOTIC RESISTANCE 
1.1.1 Golden Era of Antibiotics 
Penicillin was discovered accidentally in 1928 by Alexander Fleming, a Professor of 
Bacteriology at St. Mary’s hospital in London (1). A derivative from the common bread mold 
Penicillium, it appeared as a green, fuzzy substance inhibiting Staphylococcus growth on an old 
petri dish. This chance observation, coupled with the successful isolation and mass-production of 
penicillin in the 1940s by Oxford researchers Sir Howard Florey and Ernst Chain, ushered in a 
new era of medicine, one in which minor cuts and scrapes, as well as serious infectious diseases 
such as diphtheria, pneumonia, and scarlet fever, no longer posed a potentially deadly threat to 
much of the developed world. Fleming, Florey, and Chain shared the 1945 Nobel Prize for 
Medicine as a result of their work (2, 3). 
 The “Golden Era” of antibiotic use and discovery had thus begun. In the period from the 
1940s to the 1960s, researchers identified new antimicrobials mainly by screening soil-derived 
microbes, which led to the discovery of streptomycin, chloramphenicol, and many other 
antimicrobials (4, 5). In fact, about one-half of the antibiotics commonly used today in a clinical 
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setting were discovered within the period from 1950 to 1960 (6). No new classes of antibiotics 
have been discovered since the 1970s (7). 
  During the 20th century, deaths as a result of infectious diseases in the United States 
declined significantly, from 797 deaths per 100,000 in 1900 to 36 deaths per 100,000 in 1980 (8). 
The leading causes of death had shifted from infectious to chronic disease; in 1900, the top two 
causes of death were pneumonia and tuberculosis, while heart disease and cancer led mortality 
rates by 1997 (9). The control of infectious diseases evident throughout the 20th century can be 
attributed to many factors, including better sanitation and hygiene measures as well as 
vaccination, but the concurrent role of antibiotics and other antimicrobial measures cannot be 
understated (9). In World War II alone, penicillin saved thousands of wounded soldiers and 
civilians from dying of bacterial infections (10). 
By the end of the 20th century, new challenges in public health had begun to emerge: 
human immunodeficiency virus (HIV) appeared, along with the emergence of drug-resistant 
tuberculosis. An overall increase in morbidity and mortality in the last twenty years of the 
century emphasized the ability of microbes to evolve, as well as the need for disease prevention 
methods of public health intervention which did not rely so heavily on antibiotic use alone (11). 
1.1.2 Emergence of Resistance 
Antimicrobial resistance (AMR) occurs when microbes evolve upon exposure to antimicrobial 
agents, rendering them refractory to inhibition by the drug. Antibiotic resistance refers 
specifically to bacterial resistance against these drugs, though the terms are often used 
interchangeably.  
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  Bacterial resistance to antimicrobials occurs in nature. Because many antibiotics are 
naturally-derived compounds (particularly those from the soil), it makes sense that some species 
of bacteria are intrinsically resistant to certain antibiotics due to evolutionary competition 
between microbes. Intrinsic resistance to penicillin, for example, was observed in 1940, shortly 
after its discovery and before widespread clinical use (12). However, the main focus of the 
public health problem of antimicrobial resistance is acquired resistance in a bacterial population 
which was originally susceptible to the antimicrobial compound (13).  
  Shortly after penicillin was introduced on a widespread clinical scale in the 1940s, 
acquired resistance began to emerge; so much so, that by the 1950s, many of the gains of the 
prior decade were threatened (14). In response, researchers discovered and deployed new beta-
lactam antibiotics, and through the 1960s and early 1980s, the pharmaceutical industry 
introduced many new types of antibiotics to combat the growing resistance problem (15). 
However, in the early 1980s, the antibiotic pipeline began to dry up, with fewer new drugs being 
introduced to the public. Today, resistance has been seen to nearly all antibiotics that have been 
developed. With a lack of new antibiotics, as well as behavioral factors propagating resistance, 
bacterial infections have again become an urgent public health threat (10). 
1.1.3 Causes of Antibiotic Resistance 
Indiscriminate antibiotic use in humans (both overuse and inappropriate prescribing) is a 
significant factor which adds to the selective pressure for bacteria to develop strategies to escape 
eradication, thus resulting in acquired resistance (16). Epidemiological studies have shown there 
is a direct relationship between antibiotic consumption and the emergence and dissemination of 
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resistant bacteria strains, while incorrect prescription of antibiotics exposes individual patients to 
potential complications of antibiotic therapy without any therapeutic benefit (17, 18).  
 Another contributing factor to antibiotic resistance is extensive agricultural use. 
Approximately 80% of the antibiotics sold in the United States are used for animal agriculture 
(19). It is common practice to feed animals a consistent, low dose of antibiotics to encourage 
weight gain and to prevent infections, in addition to using these drugs to treat serious infections 
and assist with surgical procedures in animals (20).  This widespread use of antibiotics in 
livestock contributes––by means of natural selection––to the emergence of antimicrobial-
resistant bacteria and has significant public health implications including environmental and 
food-borne transmission of resistant bacteria to humans, as well as transmission to agricultural 
workers via direct contact (21).   
  Lastly, few new antibiotics have been developed since the 1980s. To combat threats of 
resistance in the past, pharmaceutical companies had devoted resources to discovering new 
antimicrobial agents. However, due to both regulatory and economic hurtles, this strategy has 
been stalled. Economically, there is less financial incentive for pharmaceutical companies to 
pursue research of novel antibiotics. Because antibiotics are used for relatively short periods and 
are often curative, companies prefer to invest in more profitable drugs for chronic diseases such 
as diabetes and psychiatric disorders (22). The low cost, availability, and ease-of-use of 
antibiotics, combined with the desire of clinicians to use new drugs judiciously in a clinical 
setting leads to a diminished return on investment for these drugs as well, further 
disincentivizing pharmaceutical companies from pursuing novel antimicrobial research (23). 
Regulatory obstacles often include differences in clinical trial requirements among countries, 
changes in regulatory and licensing rules, and ineffective channels of communication (22). As a 
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result, due to a shortage of novel antimicrobial agents, many researchers are re-evaluating older 
antibiotics and their efficacy against a variety of both gram-negative and gram-positive 
pathogens (24, 25).   
1.2 WHO PRIORITY PATHOGENS 
The World Health Organization (WHO) has determined that antibiotic resistance requires urgent, 
coordinated action at global, regional, and national levels (26) . The WHO has conducted an 
annual evaluation of the antibacterial clinical development pipeline, based on an in-depth 
analysis conducted by an advisory group of clinicians, microbiologists, and other antibiotic 
resistance experts. In this report, the organization lists twelve priority pathogens on which it 
believes research and development efforts should be focused. 
The top WHO priority pathogen is tuberculosis (TB), caused by the gram negative -
Mycobacterium tuberculosis. TB is the number one global infectious disease killer, causing 
nearly 2 million deaths per year (27). Drug-resistant TB is the most common and lethal airborne 
AMR disease worldwide today, causing 250,000 deaths per year (28). For multi-drug resistant 
TB, which includes strains of the disease resistant to first line treatments of both rifampin and 
isoniazid, disease burden and treatment outcome has been particularly difficult to improve (26). 
Other WHO critical priority pathogens include a mix of gram-negative and gram-positive 
pathogens, such as Pseudomonas aeruginosa, Enterobacteriaceae, vancomycin-resistant 
Enterococcus faecium (VRE), and Staphylococcus aureus. 
Gram-negative bacteria currently pose a serious global threat to public health. However, 
there exists a clear and pressing need to develop new antimicrobials against gram positive 
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organisms as well. Multi-drug resistant gram-positive bacteria, including VRE and methicillin-
resistant S. aureus (MRSA), as well as drug-resistant S. pneumoniae have been designated as 
serious public health threats by the US Centers for Disease Control and Prevention (CDC) (29). 
Both VRE and MRSA are common causes of bloodstream and other infections in hospitalized 
patients in the United States causing upwards of 12,000 deaths per year, and infections due to 
drug-resistant S. pneumoniae are estimated to cause approximately 7,000 deaths per year in the 
United States (29, 30). By focusing research efforts on developing or expanding the use of 
existing antibiotics which target both gram-negative and gram-positive organisms, we can target 
a greater range of resistant bacteria and maximize public health impact.  
1.3 FOSFOMYCIN 
Fosfomycin is an old antibiotic, discovered from Streptomyces in 1969, and is effective against 
both gram-negative and gram-positive bacteria (31). It is highly active against extended spectrum 
β-lactamase (ESBL)-producing E. coli, with MIC50 and MIC90 values (minimum inhibitory 
concentrations that inhibit 50% and 90% of the isolates, respectively) generally falling between 2 
and 4 mg/L (32). ESBL-producing bacterial strains are particularly feared as they are resistant to 
all penicillins, to cephalosporins (including third and fourth generation agents), and to 
aztreonam, and they are often cross-resistant to trimethoprim/sulfamethoxazole and quinolones 
as well (33).  
Due to fosfomycin’s broad spectrum antimicrobial activity, its effectiveness against 
MDR E. coli, and faced with a paucity of novel antibiotics, physicians have reconsidered it for 
use against a variety of both gram-negative and gram-positive MDR pathogens (32).  
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1.3.1 Clinical Use 
Fosfomycin is commonly prescribed orally as a first-line treatment against uncomplicated 
urinary tract infections (UTIs), and functions as an inhibitor of the bacterial enzyme MurA (see 
Chapter 1.4).  In a few European countries, fosfomycin is approved to be administered 
intravenously to treat soft-tissue infection and sepsis (34). As previously mentioned, fosfomycin 
is effective against several species of ESBL-producing bacteria, and because of this it has been 
used in clinical trials in combination with other antimicrobials to successfully treat nosocomial 
infections caused by ESBL-producing carbapenem-resistant K. pneumoniae (35). 
1.3.2 Resistance 
Though fosfomycin is highly effective against ESBL-producing E. coli, its susceptibility is 
decreased in some other species of MDR bacteria. In ESBL-producing carbapenem-resistant K. 
pneumoniae, the MIC50 and MIC90 values are significantly higher than in E. coli (~32 mg/L and 
~128 mg/L, respectively), translating to susceptibility rates of ~ 80%. Data on other species are 
scarce, but Enterobacter spp., Proteus spp. and P. aeruginosa have susceptibility rates of ~ 70% 
(36, 37). 
The most clinically relevant mechanism of fosfomycin resistance involves expression of 
FosA3, an enzyme which catalyzes the Mn2+- and K+-dependent glutathione-mediated 
degradation of fosfomycin (38). Epidemiologically this enzyme was initially identified in Japan 
but has subsequently been shown to be widespread in East Asia in ESBL-producing E. coli and 
less commonly in K. pneumoniae from humans (38, 39). The FosA3 enzyme confers intrinsic 
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resistance in some species of bacteria, and the fosA3 gene can also spread plasmid-mediated 
resistance among different species in the Enterobacteriaceae family (38).   
Other resistance mechanisms to fosfomycin, including intrinsic resistance observed in 
VRE isolates at the University of Pittsburgh Medical Center (UPMC) involve its target, the 
bacterial enzyme MurA (40).  
1.4 MurA 
UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is a bacterial enzyme which 
catalyzes the transfer of enolpyruvate from phosphoenolpyruvate (PEP) to uridine diphospho-N-
acetylglucosamine (UNAG), the first committed step of bacterial cell wall biosynthesis (Figure 
1) (41). Fosfomycin is currently the only antibiotic which targets MurA, and functions by 
forming a covalent bond with the Cysteine115 residue in the active site of MurA, thereby 
inhibiting its function and resulting in bacterial cell death (Figure 2) (34).  
 
Figure 1. Reaction catalyzed by MurA. 
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Figure 2. Fosfoycin is ineffective against bacteria with the Cys-Asp mutation in the MurA active site. 
  
MurA variants which lack this cysteine residue in the active site are intrinsically resistant to 
fosfomycin. These species include M. tuberculosis and B. burgdorferi, which encode an 
Aspartate residue in place of Cys115 in the MurA active site. Previously mentioned VRE isolates 
discovered at UPMC also possess an Asp residue in place of the Cys115 in the active site of 
MurA (40). 
Fosfomycin is ineffective against bacteria with the Cysteine-to-Aspartate amino acid 
change within the MurA active site. However, MurA is an extremely ubiquitous enzyme, and is 
highly conserved among bacteria, is essential for cell survival, and has no human homolog, all of 
which make it a desirable drug target (42). Therefore, identifying a MurA inhibitor that is active 
against both intrinsically fosfomycin-resistant MurA and fosfomycin-susceptible variants – 
which include WHO priority pathogens such as M. tuberculosis - is a logically sound research 
pursuit.      
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The goal of this study was to identify novel MurA inhibitors which have a different 
mechanism of action than fosfomycin, and which are active against a range of gram negative and 
gram positive bacteria. With luck, these novel inhibitors will serve as an antimicrobial agent that 
is clinically effective against both fosfomycin-sensitive and fosfomycin-resistant bacteria. 
To that end, we purified two primary enzymes: VRE WT MurA, which contains the 
conserved Cys115 residue in the active site, and VRE C119D MurA, which contains as Asp 
residue at position 119. Using an in vivo high-throughput screen, we screened both enzymes 
against the TimTec® ApexScreen library, which contains 5,040 structurally diverse compounds, 
in search of a drug which inhibits both the wildtype and C119D substitution forms of MurA. 
Because these overlap hits inhibit both variants of the MurA enzyme, they likely have a different 
mechanism of action than fosfomycin, which exclusively targets Cys115 in wildtype MurA, and 
therefore may be useful compounds in expanding the clinical use of fosfomycin. After 
identifying these overlap hits, their inhibitory activity was further validated using bacterial 
growth curves, toxicity assays, and other methods. 
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2.0  SPECIFIC AIMS 
2.1 PROJECT STATEMENT 
The use of high-throughput screens for antibiotic drug discovery is not a novel concept; however 
it still remains a highly useful technique in the age of antibiotic resistance. This project uses 
high-throughput screens to sift through the TimTec® ApexScreen library of over 5,000 
compounds to find a bacterial MurA enzyme inhibitor, which may eventually be used to replace 
or expand the use of fosfomycin in the clinical setting. The overall goal of this project is to 
identify and characterize an inhibitor(s) with a different mechanism of action than fosfomycin, so 
that bacterial species with intrinsic resistance to fosfomycin may be potential targets.    
2.2 PROJECT SPECIFIC AIMS 
2.2.1 Specific Aim 1: To screen the TimTec® ApexScreen Library for potential MurA 
inhibitors. 
A. Using malachite-green based assays, primary and secondary screens were performed 
on the TimTec® ApexScreen Library. Results were quantified by spectroscopy and 
analyzed in Microsoft Excel.  
 12 
B. An artefact screen using malachite green was also performed on remaining hits. 
Results were quantified by spectroscopy. 
2.2.2 Specific Aim 2: To characterize promising hits identified from the high-throughput 
screens. 
A. MIC assays were performed by incubating various species of bacteria with a given 
inhibitor for 24 hours. Results were quantified visually. 
B. Toxicity assays were performed by incubating various concentrations of inhibitor 
with both HeLa and 293T HEK cell lines for 24 hours. Results were quantified by 
luminescence spectroscopy.  
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3.0  MATERIALS AND METHODS 
3.1 RECOMBINANT PROTEIN EXPRESSION AND PURIFICATION 
VRE isolates were obtained from patients via rectal screening at the University of Pittsburgh 
Medical Center, Pittsburgh, PA, USA. 890 of these isolates were screened for resistance to 
fosfomycin, and 4 of these isolates had MICs >1024μg/mL for fosfomycin, indicating resistance. 
After amplification and sequencing it was determined that these isolates possessed a Cys119Asp 
(C119D) substitution in the active site of MurA. The half-maximal inhibitory concentrations 
(IC50) of fosfomycin for both WT and C119D were determined as well as other kinetic 
parameters (40). There is no difference in MurA activity of the C119D variant when exposed to 
very high levels of fosfomycin, while the wildtype Cys115 variant remains sensitive (Figure 3). 
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Figure 3. Half maximal inhibitory concentrations of fosfomycin acting on MurA. There is no difference in MurA 
activity of the C119D variant when exposed to very high levels of fosfomycin. 
 
VRE WT, VRE C119D, and M. tuberculosis murA genes were synthesized (Genscript, 
Piscataway, NJ, USA) and cloned into a pE-SUMOstar prokaryotic expression system 
(LifeSensors, Malvern, PA, USA), and transformed into BL21 (DE3) pLysS competent E. coli 
cells with small-ubiquitin-related modifier (SUMO) and His6 fusion tags.  The hexahistidine 
SUMO fusion construct has been shown to enhance expression and facilitate purification with 
Ni-NTA chromatography, particularly with difficult-to-express proteins, when compared to 
traditional gene fusion systems (43). Transformed E. coli were grown overnight at 37 deg 
Celsius in Power Prime Broth with 100mg/L ampicillin. Overnight cultures were diluted 1:50 in 
fresh Power Prime broth, and grown to an optical density (OD) of 0.3 measured at 600nm before 
expression was induced for four hours using 1mmol/L isopropyl β-D-1-thiogalactopyranoside 
(IPTG). After expression, cells were obtained by centrifugation and resuspension in 50mmol/L 
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sodium phosphate buffer with protease inhibitor, and then lysed mechanically using a French 
press.  
Cell supernatants were mixed with TALON Metal Affinity Resin (Clontech Laboratories, 
Inc., Mountain View, CA, USA), loaded into a gravity flow column, and washed with sodium 
phosphate buffer plus 0.3mol/L NaCl and 1 mmol/L β-mercaptoethanol. Bound protein was 
eluted with 100 mmol/L sodium phosphate containing 0.6mol/L NaCl, 240mmol/L imidazole, 
and 1 mmol/L β-mercaptoethanol. The protein was exchanged into 25 mmol/L Tris-HCl by using 
an NAP-25 column (GE Healthcare, Chicago, IL, USA). Protein concentration was determined 
with a Bradford assay with bovine serum albumin (BSA) as the standard. Purification was 
evaluated with a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
M. tuberculosis yield was too low to proceed, but the VRE WT and C119D variants had robust 
yields. The VRE purified proteins were then aliquoted and stored in 25% Glycerol at -80 deg 
Celsius for later use. 
3.2 TIMTEC® APEXSCREEN DRUG LIBRARY 
The TimTec® ApexScreen drug library (TimTec, Inc., Newark, DE, USA) was selected due to 
its diversity and quantity of structurally active compounds. Each compound in this library obeys 
the Lipinski Rule of Five indicating a likelihood to display good oral bioavailability, solubility, 
and permeability profiles (44). 
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3.3 HIGH-THROUGHPUT SCREENING ASSAY: MALACHITE GREEN 
The reaction catalyzed by MurA results in the production of UDP-N-acetylpyruvylglucosamine 
and free inorganic phosphate (Figure 1). The primary assay used in the high-throughput screen is 
the Malachite Green Phosphate Assay Kit (BioAssay Systems, Hayward, CA, USA), a 
colorimetric 96-well assay which changes color in the presence of free inorganic phosphate in 
solution. When the MurA reaction proceeds, inorganic phosphate is produced, and a color 
change to occurs from yellow to green. When the MurA reaction is inhibited, inorganic 
phosphate is not produced and the color of the reagent remains yellow (Figures 4 and 5). 
 
 
Figure 4. Before the reaction proceeds, all wells are yellow. 
 
 
Figure 5. When the reaction proceeds, wells turn green. 
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1μL of each TimTex ApexScreen compound per well was incubated with PEP, UNAG, 
and enzyme in 96-well plates, and the reaction was quenched after 20 minutes as per the 
manufacturer recommendation. Enzyme and no-enzyme controls were also prepared with DMSO 
instead of drug in each plate (Figure 5). In total, 63 VRE WT plates were screened and 63 VRE 
C119D plates were screened in parallel during the primary screen for both enzymes. 
 
 
Figure 6. Example plate with positive and negative controls in quadruplicate. 
 
The malachite green color change allowed for visual determination whether the MurA 
reaction was proceeding in each well of a 96-well plate (Figure 6). Absorption spectroscopy was 
also used to quantify the amount of free inorganic phosphate in solution. This data was imported 
into Microsoft Excel. Absorption data was scaled from 0 to 1 based on enzyme and no-enzyme 
controls, and a “Heat Map Analysis” was constructed to more easily compare data between 
plates. The criteria for a hit was 70% or greater reaction inhibition (phosphate absorption values 
from 0.000 to 0.300 out of 1.000). 
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Figure 7. Plate map for high-throughput primary enzyme screen. 
 
A drawback of the malachite green assay is its sensitivity to bubbles in each well, which 
may result in a false-positive hit reading as a result of natural variation in pipetting technique. To 
eliminate these potential false-positive hits, the VRE WT enzyme underwent a secondary 
screening using the same assay technique, and any hits not validated by the second screen were 
eliminated.  
For the C119D enzyme, which resulted in a much smaller number of primary hits, 
primary hits were screened for pan-assay interference compounds (PAINs) using the BadApple 
scoring database. PAINs are molecules which are known to indiscriminately bind to substrate 
and result in false-positives in drug-screening (45). Once the PAINs molecules were eliminated, 
the WT and C119D results were compared in order to identify overlap hits, which were then 
further screened using an artefact assay. 
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3.4 ARTEFACT SCREEN 
The artefact assay also implemented malachite green. Potential hits were incubated with 
pyrophosphate and no enzyme; absorption data was collected at 620nm and any wells with a 
reduction in absorption were considered artefacts and eliminated from consideration. 
3.5 MIC ASSAY 
The Minimum Inhibitory Concentration (MIC) is defined as the lowest concentration of an 
antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation 
(46). MICs for remaining hits were conducted in 96-well plates with four bacterial strains: 
wildtype vancomycin resistant Enterococcus faecium, vancomycin resistance Enterococcus 
faecium with the C119D substitution, Staphylococcus aureus, and Escherichia coli. Both the S. 
aureus and E. coli are commercially available strains and were used as controls. Bacteria were 
incubated with fosfomycin, inhibitor, or DMSO overnight at a range of concentrations (Figure 
7). Growth in each well was visually determined the following day. 
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Figure 8. Example plate map for compound P24C4 MIC assay. 
3.6 TOXICITY ASSAY 
Toxicity assays on remaining hits were conducted using 96-well plates with two different cell 
lines. Standard cell culture methods were used to grow TZM-bl HeLa cells as well as 293T 
Human Embryonic Kidney (HEK) cells. For each assay, approximately 180μL of Dulbecco’s 
Modified Eagle Medium (DMEM) containing approximately 20,000 cells per well was incubated 
at 37 deg Celsius with 20μL of inhibitor, DMSO control, or media control at varying 
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concentrations (Figure 8). After 24 hours of incubation, each well received 100μL of CellTiter-
Glo® Luminescent Cell Viability Assay reagent (Promega, Madison, WI, USA) as per 
manufacturer recommendation. The CellTiter-Glo® assay determines the number of viable cells 
in culture based on quantitation of ATP (47). Luminescence was quantified via spectroscopy. 
 
Figure 9. Example compound P24C4 toxicity assay plate map. 
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4.0  RESULTS 
4.1 AIM 1: HIGH-THROUGHPUT SCREENS 
4.1.1 Enzyme Purification 
VRE WT, C119D, and M. tuberculosis (TB) MurA enzymes were purified using standard 
methods as described in Chapter 3. An SDS-PAGE gel was run to confirm presence of purified 
protein (Figure 10). The molecular weights of VRE WT and C119D enzymes are ~44kD, and the 
molecular weight of TB MurA is ~47.4kD. The weak bands in the TB column contrast with the 
robust bands for both WT and C119D MurA. VRE WT and C119D MurA enzymes were stored 
in 50% glycerol at -80 deg C. 
 
 
 
 
 
 
 
 
Figure 10. SDS-Page Gel confirming presence of purified MurA enzymes. 
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4.1.2 Primary and Secondary Screens 
Enzymes were screened against the library of potential inhibitors using a malachite-green assay 
(as described, along with a plate map, in Chapter 3). Potential hits were validated by a secondary 
screen. Data from a representative plate (Plate 43 out of 63 plates in the primary screen) is shown 
here for brevity. 
   
 
 
 
 
Figure 11. Representative plate from primary screen. 
 
Figure 10 illustrates a representative plate from the primary drug library screen. The dark green 
wells represent reactions which have proceeded fully, while the yellow wells represent a 
potential MurA inhibition reaction. The uppermost left four and lowermost right four wells 
represent positive controls where we expect the enzymatic reaction to proceed fully, while the 
lowermost right four and uppermost left four wells are the negative controls without enzyme, 
where we expect no reaction to occur. Each of these plates was read at 620nm on a 
spectrophotometer to quantify the reaction in each well, and these readings were standardized on 
a scale from 0 to 1 to generate a color-coded heat map on Microsoft Excel, and to more easily 
compare data between plates. 
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  The VRE WT and C119D MurA enzymes were concurrently screened against the drug 
library, and a heat map was created for each plate in the screens. A representative heat map of 
VRE WT Plate 43 can be seen in Figure 11, while a heat map for C119D MurA can be seen in 
Figure 12. Figure 13 is a scatterplot of the WT and C119D plate 43 screening data.  
 
Figure 12. Representative heat map for VRE WT plate 43. 
 
Figure 13. Representative heat map for VRE C119D plate 43. 
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Figure 14. Scatterplot of WT and C119D hits from plate 43 of the primary drug screen. 
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The primary drug screen for the VRE WT MurA generated over 910 hits, which is an 
unfeasible number of molecular interactions to characterize within the scope of this study. 
Therefore, a secondary screen was carried out to validate the initial WT hits. Daughter plates 
were created from the hits of the original drug library, and another series of malachite green 
assays were performed. A representative plate (plate 12 out of 12 WT daughter plates) is shown 
in Figure 14. The green wells indicate reactions which have generated inorganic phosphate, 
while the yellow-orange wells indicate reactions which did not produce inorganic phosphate. 
 
Figure 15. Representative daughter plate 12 from secondary drug screen. 
 
After the secondary WT screen, 775 hits were validated, and the hit rate was reduced from 
18.06% to 15.38%. The number of C119D primary screen hits was 182, with an initial hit rate of 
3.6%. After the primary C119D hits were identified, they were cross-checked against the 
BadApple scoring system database to eliminate PAINs (see Chapter 3), which reduced the 
C119D hit rate from 3.6% to 1.2%, a much more feasible number of compounds to further 
analyze. At this point, 128 hits from the WT and C119D screens were determined to be overlaps, 
and the overall hit rate between the two enzymes was 2.54%. 
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4.1.3 Artefact Screen 
To screen for artefacts, the overlap hits were incubated in 96-well plates with deionized water 
and pyrophosphate, but with no enzyme. Because the enzyme was not present in any wells, any 
compound which disrupted the pyrophosphate signal was determined to be an artefact and 
eliminated from further consideration. Pyrophosphate was measured via spectrophotometer at 
620nm. Signal disruption criteria was determined to be any well with a signal of less than 1.000.  
Figure 16. Artefact assay, plate 1. 
Figure 17. Artefact assay control plate 1. 
 
 
  
Figure 18. Artefact assay control plate 2. 
 
 
 
 
Figure 19. Artefact assay, plate 2. 
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Heat maps of the artefact assay, carried out in two plates, can be seen in figures 15 and 17. The 7 
validated hits from the artefact screen are bolded in these figures, while the deionized water 
controls can be seen in Figures 16 and 18. A scatterplot of this data can also be seen in Figure 19 
with validated hits in red. The artefact screen reduced the overall hit rate from 2.54% to 0.14%.  
. 
 
  
 
 
 
Figure 20. Scatterplot of artefact screen data 
 
 
After the artefact screen, 7 hits remained. Preliminary in vitro data was conducted to further 
whittle down the list of potential hits to characterize.   
4.1.4 In vivo screening* 
Two groups of thirty wells were set up containing Müller-Hinten broth, 25μg/mL glucose-6-
phosphate, and one of the following: no drug, 1% DMSO, 1% compound in DMSO, or 
1024μg/mL fosfomycin. These were inoculated with ~5x105 CFUs of either VRE WT or C119D 
bacteria and grown for 24 hours at 35 deg C. As expected, the C119D grew in the presence of 
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fosfomycin, despite it killing WT. Additionally, 6 compounds inhibited growth of both VRE WT 
and C119D, which can be seen in Figure 20.  
 
 
Figure 21. Plate results for in vivo screening. Bacterial growth is shown in red, while non-growth in shown in 
green. 
 
The half maximal inhibitory concentrations (IC50s) were determined for these remaining six 
compounds as well as three previously purchased compounds, and the IC50s of the four most 
promising compounds can be seen in Figures 21 - 24. 
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*The in vivo and IC50 data in this section was provided courtesy of Adam Tomich in the Sluis-Cremer Lab.  
   
Compounds P24C4 and P31A4 had the lowest IC50 values at 39.53 and 3.301 
respectively. P22E7 also had a promising IC50 curve despite its higher IC50 value. These three 
compounds were selected for further consideration. The hit rate for each stage of high- 
Figure 25. P33A7 IC50 curve. Figure 24. P22E7 IC50 curve. 
Figure 23. P24C4 IC50 curve. Figure 22. P22E7 IC50 curve. 
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throughput screening can be seen in Table 1. After these hits were validated, we proceeded to 
further characterize these compounds in bacteria and in human cell lines. 
 
Table 1. High-throughput screen hit rate. 
      Hit Rate 
Total # Compounds: 5040     
        
Primary Screen WT Hits: 910   18.06% 
        
Secondary Screen WT Hits: 775   15.38% 
        
Overlap WT + C119D hits: 128   2.54% 
        
 Artefact Screen hits: 7    0.14% 
        
Preliminary in vitro hits: 3   0.060% 
 
4.2 AIM 2: INHIBITOR CHARACTERIZATION 
4.2.1 MIC Assay 
To determine the MICs of each compound, VRE WT and C119D were used as bacterial strains 
of interest along with commercially available strains of E. coli and S. aureus for gram-negative 
and gram-positive controls, respectively. Two trials were performed with each MIC assay; 
results from one trial of each compound are shown for brevity in figures 25 – 27, and tables 2 – 
4.  
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Figure 26. Representative MIC results for compound P22E7. 
In Figure 26, VRE WT bacteria is susceptible to fosfomycin, while the C119D bacteria is 
not. P22E7 kills both VRE WT and C119D bacterial strains, and kills S. aureus, but not E. coli.   
  
  
  
  
  
  
  
  
  
  
  
 
Figure 27. Representative MIC results for compound P24C4. 
 32 
In Figure 27, VRE WT is again susceptible to fosfomycin, while VRE C119D is not. 
P24C4 killed VRE WT at a higher dose than fosfomycin, and also killed VRE C119D bacteria. 
While P24C4 killed S. aureus, it did not affect E. coli. 
 
 
 
 
 
 
 
 
  
 
Figure 28. Representative MIC results for compound P31A4. 
In Figure 28, compound P31A4 is effective against both VRE WT and C119D bacteria, 
and like the other two compounds is effective against gram positive S. Aureus while not being 
effective against gram negative E. coli. The average MIC values for P22E7 (Table 2) are 
comparable in both VRE WT and C119D bacterial strains at 0.1-0.2μg/mL, while the MIC in S. 
aureus is much higher for P22E7 than for fosfomycin.  
 
Table 2. P22E7 average MIC values. 
Avg Strain 
Drug 
(μg/mL) VRE WT C119D S. aureus E. coli 
Fosfomycin 64 >1024 2-4 1 
P22E7 0.1-0.2 0.1-0.2 0.1 >112 
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The average MIC values for P24C4 (Table 3) are about the same in VRE WT, C119D, 
and S. aureus bacteria, while exceeding the maximum inhibitor concentration in E. coli. 
Fosfomycin has lower MIC values than P24C4 in both S. aureus and E. coli strains.  
 
Table 3. P24C4 average MIC values. 
Avg Strain 
Drug 
(μg/mL) VRE WT C119D S. aureus E. coli 
Fosfomycin 128 >1024 1-8 1 
P24C4 20 10-20 20 >80 
 
The average MIC values for P31A4 (Table 4) were very similar in VRE WT, C119D, and 
S. aureus, while the P31A4 MIC was much higher in E. coli than the fosfomycin MIC for this 
strain. 
 
Table 4. P31A4 average MIC values. 
Avg Strain 
Drug 
(μg/mL) VRE WT C119D S. aureus E. coli 
Fosfomycin 128 >1024 1-2 1 
P31A4 0.55 0.55 0.55-1.09 >70 
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4.2.2 Toxicity Assays 
After the MIC values for each compound were determined, toxicity assays were performed using 
two cell lines: HeLa (a cervical cancer cell line) and 293T HEK (a human kidney cell line). 
Compounds were incubated with each cell line at varying concentrations above and below 
respective MIC values. Figures 29-36 illustrate percentage of cell viability vs an array of 
concentrations of a given compound.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. HeLa incubated with [P31A4]. 
Figure 31. HeLa incubated with [P22E7]. Figure 32. HeLa incubated with DMSO controls. 
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Figure 30. HeLa incubated with [P24C4]. 
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When HeLa cells were incubated with varying concentrations of P24C4 (ranging from 
1.85 μg/mL to 150 μg/mL), cells remained close to 100% viable until incubated with a dose of 
50.00 μg/mL inhibitor, when the viability decreased to approximately 75%. For cells incubated 
with the same range of concentrations for P31A4, the percent viability dropped below the DMSO 
control for 16.67μg/mL inhibitor. The P22E7 inhibitor resulted in the lowest percentage of cell 
viability across the board, with the most concentrated dose rivaling the cell viability of the 10% 
DMSO control. The 10% DMSO controls in each assay all resulted in significantly low cell 
viability for both cell lines. The percentage of cell viability for cells incubated with the varying 
lower concentrations of DMSO were approximately 100%, except for the 10% DMSO treatment 
which resulted in approximately 10% of cell viability. 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 34. 293T incubated with [P24C4]. Figure 33. 293T incubated with [P31A4]. 
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When 293T cells were incubated with the same range of concentrations of P24C4, cells 
again remained nearly 100% viable until incubated with a dose of 50.00μg/mL, where the cell 
viability dropped to approximately 75%. When incubated with P31A4, cell viablity dropped 
significantly below the viability of the 10% DMSO control when incubated with 16.67μg/mL. 
For the cells incubated with P22E7, there is a decrease of cell viability in a dose-dependent 
fashion as concentration of P22E7 is increased. Again, cell viablity was about 100% for cells 
incubated with DMSO controls at these same concentrations, with the exception of 10% DMSO 
where cells had about a 20% viability. All cells incubated with varying concentrations of DMSO 
demonstrated a cell viability of nearly 100% with the exception of the 10% DMSO control, 
which hovered around 25%. 
Figure 36. 293T incubated with [P22E7]. Figure 35. 293T incubated with DMSO controls. 
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4.2.3 Selectivity Indexes 
A further value which may help elucidate therapeutic potential for these drugs is the 
selectivity index. Selectivity indexes (SIs) were calculated from the MIC assays and toxicity 
assays (SI = CC50/MIC), and can be seen below in Table 5. 
 
Table 5. Inhibitor selectivity indexes. 
Inhibitor Selectivity Index 
P24C4 5 
P31A4 10.9 
P22E7 9.25-18.5 
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5.0  DISCUSSION 
5.1 ENZYME PURIFICATION 
Weak bands for TB MurA enzyme indicate little presence of TB MurA, which suggests a low 
yield from protein purifications. The project subsequently proceeded with only VRE WT and 
VRE C119D MurA enzymes. Because one of the potential applications of a MurA inhibitor may 
be to treat bacterial infections caused by M. tuberculosis, it would be of interest to purify TB 
MurA and screen it against a drug library in a similar manner. 
5.2 PRIMARY AND SECONDARY SCREENS  
Positive and negative enzyme controls were averaged in data analysis. Any outlier wells were 
dropped from data analysis, though this incident only occurred a handful of times over the 
hundreds of plates used in primary and secondary screens.  
As a general trend, there were significantly more hits identified in the primary screen for 
VRE WT MurA than for VRE C119D. The stark difference in number of initial hits may be due 
to the substitution from cysteine to aspartic acid in the active site of the MurA enzyme. Cysteine 
is a small, polar, amino acid, while aspartic acid is a much larger and acidic residue, so we 
speculate that differences in steric interactions may have resulted in the discrepancy between 
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numbers of initial hits. In addition, raising of the 70% inhibition threshold would have resulted in 
a smaller number of hits. 
  It is also important to mention that the TimTec® ApexScreen drug library used in the 
project has also been used in other experiments within the Sluis-Cremer lab. Because the amount 
of drug in each well of the library may have been depleted in some cases, a decreased amount of 
some drugs may have been deposited in some of the assay plates, resulting in potential false-
negative hits. Careful pipetting technique was implemented to minimize determination of false-
negative hits. 
5.3 ARTEFACT SCREEN 
The threshold for validation in the artefact screen was determined to be any spectrophotometer 
reading above 1.000, though we recognize that a lower threshold would have validated more hits 
to further analyze. Following up with some of the hits in the artefact screen at a slightly lower 
threshold may be of interest to others looking to identify MurA inhibitors. 
5.4 MIC ASSAYS 
Controls for the MIC assays are unremarkable; fosfomycin is active against WT but not C119D, 
which is expected as the C119D bacterial strain does not contain fosfomycin’s target cysteine 
residue in the MurA active site. P22E7 results suggest that this inhibitor may require a smaller 
dose to kill bacteria than fosfomycin, but its activity against S. aureus coupled with its 
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ineffectiveness against E. coli suggest gram-positive specificity. P22E7 was also active against 
both VRE WT and C119D bacteria which strongly implies a different mechanism of action than 
fosfomycin. 
  P24C4 results suggest a comparable dose required to kill VRE WT bacteria, and P24C4 
is also effective against C119D bacteria, which again suggests a different mechanism of action of 
MurA inhibition than fosfomycin. P31A4 required a smaller dose than fosfomycin to kill VRE 
WT bacteria, and was also effective against VRE C119D. Both P24C4 and P31A4, like P22E7, 
appear to have gram-positive antibacterial specificity, which would render them inactive against 
gram-negative pathogens such as bacterial infections caused by M. tuberculosis. However, 
results seemed promising enough to proceed with toxicity assays. 
5.5 TOXICITY ASSAYS 
5.5.1 HeLa cells 
HeLa cells were chosen due to their ubiquitous nature, as well as their price and ability to grow 
rapidly and reliably as a human cell line. P24C4 appeared to become toxic starting at a dose of 
50μg/mL, while its highest MIC was determined to be about 20μg/mL, so this drop in cell 
viability may not suggest overwhelming toxicity if tested in vivo. Similarly, P31A4 experienced 
a drop in cell viability at 5.56μg/mL while its highest MIC value was 1.09μg/mL. P22E7 
however appeared to be toxic at all doses, indicating that administration of an effective dose to 
kill a given bacterial infection may also be incompatible with life of the organism. P22E7 is 
 41 
again probably too toxic to be usefully utilized in treatment of human cells, but more studies 
should be conducted to further elucidate its potential. 
5.5.2 293T cells 
293T cells were selected as a secondary cell line because they are a human kidney cell line, 
which is a likely a better model for illustrating drug toxicity than HeLa, a gynecological cervical 
cancer cell line. Because P24C4 treated 293T cells appeared to have a similar viability as the 
HeLa cell line, P24C4 is likely a promising MurA inhibitor to further investigate. P31A4 appears 
slightly less so, with cell viability dropping at 5.56μg/mL, and P22E7 was again very toxic to 
cells at any concentration. 
  Overall, further toxicity assays are required to determine a therapeutic index for these 
three inhibitors. However, based on these preliminary findings, it appears that P24C4 and P31A4 
may be promising inhibitors to further characterize while P22E7 is likely too toxic to be a useful 
antimicrobial agent in this context.   Additionally, studies examining route of drug administration 
and optimization will also need to be conducted to further elucidate interactions between these 
inhibitors, bacteria, and host cells. 
5.5.3 Selectivity Indexes 
The selectivity indexes for the three inhibitors were extremely low (5, 10.9, and 9.25-18.5 for 
P24C4, P31A4, and P22E7, respectively). Typically, drugs used clinically will have selectivity 
index values well over 100. These low SI values further indicate that there is likely not a large 
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window for therapeutic use of these inhibitors in which they can kill the pathogen without killing 
host cells.  
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6.0  CONCLUSIONS 
In conclusion, we developed a high-throughput screening assay to screen purified MurA enzyme 
against the TimTec® ApexScreen library, with the goal of identifying MurA inhibitors with a 
mechanism of action different than fosfomycin. We purified two MurA variants, VRE WT 
MurA, and VRE C119D MurA. These enzymes were both screen concurrently against the 
TimTec® Apexscreen library, and also screened for artefacts. The screens along with 
preliminary in vitro data suggested three promising candidates: P22E7, P24C4, and P31A4. 
MIC assay data illustrated that all three of these candidates are gram-positive specific, 
suggesting that these compounds would not be suitable to develop against pathogens such as M. 
tuberculosis. However, this result is not surprising because gram positive organisms tend to be 
easier to kill, due to their thicker layer of peptidoglycan within the outer membrane of the 
bacterial cell. Toxicity assays conducted in both HeLa and 293T cell lines suggest that 
compound P22E7 may be too toxic in human cells, while P24C4 and P31A4 require more studies 
to determine an accurate therapeutic index. 
Moving forward, compounds P24C4 and P31A4 should be further characterized to 
determine whether they are suitable to be used as clinical antimicrobial agents. 
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7.0  PUBLIC HEALTH RELEVANCE 
Antimicrobial resistance delays treatment of drug-resistant infections, increases the duration of 
infection, and expands the timeframe through which resistant microorganisms can spread to 
others. From a public health perspective, the patient remains a reservoir of infection for a longer 
period of time, putting community and health care workers at greater risk (48). Aside from 
complicating the treatment of infection, antibiotic resistance is associated with increased 
morbidity and mortality and significant economic loss, often resulting in prolonged hospital stays 
and thus greater financial cost to the hospital, patient, and society. The risk of these adverse 
events has been shown to be greater with drug resistant infections compared to their drug-
susceptible counterparts even when adjusting for co-morbidities (49). 
The data presented in this body of work reflects the popular strategy in recent years to re-
evaluate and expand the use of older antimicrobials to treat a broader range of drug-resistant 
infections. The compound identified in this work offers a potential inhibitor that may be 
developed into a therapeutic agent and thus expand the use of fosfomycin in a clinical setting. 
With the ability to treat both gram-negative and gram-positive infections, such an agent can be 
used to treat a broad range of potentially resistant bacterial infections, resulting in maximum 
public health impact. 
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